Key Developments: Aveo Pharmaceuticals Inc (AVEO.O)

AVEO.O on Nasdaq

6 Jul 2015
Change (% chg)

$-0.06 (-3.47%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Aveo Pharmaceuticals names Keith S. Ehrlich as Chief Financial Officer
Wednesday, 22 Apr 2015 07:00am EDT 

Aveo Pharmaceuticals Inc:Appoints Keith S. Ehrlich to the position of Chief Financial Officer.  Full Article

Aveo Pharmaceuticals announces management changes
Wednesday, 7 Jan 2015 06:30am EST 

Aveo Pharmaceuticals Inc:Appoints Michael P. Bailey as the President and Chief Executive Officer and also elected as a director, effective today.Bailey succeeds Tuan Ha-Ngoc, who will become Chairman of AVEO's board of directors.Current board Chairman, Henri A. Termeer, will become lead outside director.  Full Article

AVEO Pharmaceuticals Inc enters into research and exclusive option agreement with Ophthotech for Tivozanib (VEGF inhibitor) for treatment of Ocular Diseases
Tuesday, 11 Nov 2014 06:42am EST 

AVEO Pharmaceuticals Inc:Enters into research and exclusive option agreement with Ophthotech Corp.Under which it has provided Ophthotech an exclusive license to investigate potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for potential treatment of non-oncologic diseases of eye.Under terms of agreement, Ophthotech is obligated to pay AVEO an upfront option fee of $500,000 to investigate tivozanib as potential treatment for non-oncologic diseases of eye.  Full Article

Aveo Pharmaceuticals Inc and Biodesix, Inc. announce exploratory analysis of VeriStrat
Monday, 29 Sep 2014 06:00am EDT 

Aveo Pharmaceuticals Inc and Biodesix, Inc:Presents results from a retrospective exploratory analysis using VeriStrat, a commercially available serum protein test.The results suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.A total of 188 patients were enrolled in a randomized Phase 2 study (P6162) designed to compare the combination of ficlatuzumab and gefitinib with gefitinib alone in treatment-na├»ve Asian patients with non-small cell lung adenocarcinoma.For this retrospective exploratory analysis, 180 serum samples were assigned a VeriStrat label of either 'Good' (VSG) or 'Poor' (VSP) (VSG=145, VSP=35).No benefit was observed in the VSG subgroup in either OS (Median 24.7 mo for ficlatuzumab + gefitinib [n=69] vs not reached for gefitinib alone [n=76]; HR 1.18, p=0.492) or PFS (Median 5.6 mo for ficlatuzumab + gefitinib vs 5.6 mo for gefitinib alone; HR 1.06, p=0.753).  Full Article

Aveo Oncology Announces Lease Termination and Amendment to Debt Financing Facility
Friday, 26 Sep 2014 07:00am EDT 

Aveo Oncology:Enters into a termination of its lease agreement pertaining to the company's headquarters in Cambridge, Massachusetts, reducing its existing lease obligations by $110 mln.Company has amended its debt financing facility with Hercules Technology Growth Capital.Under the terms of its amended lease agreement with BMR-650 E Kendall B LLC, AVEO will terminate its long term lease dated May 9, 2012, in exchange for a termination fee of about $7.8 mln due upon execution of the agreement, and $7.8 mln payable over the subsequent 9 months.  Full Article

Clinical data on Aveo Oncology's Ficlatuzumab and Tivozanib to be presented at the ESMO 2014 Congress
Wednesday, 17 Sep 2014 06:00am EDT 

Aveo Oncology:Says that clinical data on ficlatuzumab, its hepatocyte growth factor inhibitory antibody, as well as tivozanib, its inhibitor of vascular endothelial growth factor 1, 2, and 3 receptors, will be presented at European Society of Medical Oncology 2014 Congress in Madrid, Spain, Sept. 26 - Sept. 30.  Full Article

Aveo and Biodesix partner to co-develop and commercialize Ficlatuzumab with a companion diagnostic for treatment of NSCLC
Thursday, 10 Apr 2014 06:30am EDT 

Aveo Pharmaceuticals Inc and Biodesix, Inc:Enters worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix((reg))companion diagnostic test.AVEO will conduct a proof of concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using the VeriStrat test (a serum protein test).Biodesix will fund up to $15 mln of cost.Expects to initiate this clinical study later this year.  Full Article

Aveo and Astellas to End worldwide collaboration & license agreement
Friday, 14 Feb 2014 06:00am EST 

Aveo Pharmaceuticals Inc:Says the company and and Astellas Pharma Inc will end their worldwide collaboration and license agreement for the development and commercialization of investigational agent tivozanib.Says Astellas has exercised its right to terminate the agreement signed in 2011 for strategic reasons, based on the clinical status of the three indications studied.Says additionally, the companies agreed to discontinue the ongoing Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC).Says the termination of the collaboration will be effective Aug. 11 at which time tivozanib rights will be returned to AVEO.Says in accordance with the collaboration and license agreement, committed development expenses will be shared equally.  Full Article

AVEO Oncology and Astellas Pharma Inc discontinue phase 2 trial of tivozanib in breast cancer
Thursday, 30 Jan 2014 06:30am EST 

AVEO Oncology:Says that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial.Says a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.Says previously announced that enrollment in this study had been slower than anticipated, and enrollment rates did not improve substantially following additional patient recruitment efforts.  Full Article

AVEO Oncology provides update on interim analysis from Tivozanib trial in colorectal cancer
Friday, 13 Dec 2013 06:50am EST 

AVEO Oncology:Says the data from a planned interim analysis of the Phase two BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.BATON-CRC, led by Astellas, is an open-label, randomized Phase two study with a primary endpoint evaluating the superiority of tivozanib in combination with modified FOLFOX6.Says data from the planned interim analysis, including biomarker data, are being analyzed, and AVEO and Astellas are in discussions regarding next steps.  Full Article

Aveo Oncology to cut two-thirds of workforce

Jan 7 - Aveo Oncology said its plans to cut two-thirds of its workforce, or 40 positions, as a part of a restructuring that includes the departure of Chief Scientific Officer Jeno Gyuris.

Search Stocks